Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations

Biomedical Chromatography

Volumn 22, Issue 11, 2008, Pages 1252-1258

  Wei, Guangli ^a,b   Xiao, Shuhua ^a   Si, Duanyun ^a   Liu, Changxiao ^a  

^a TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^b NONE   (China)

Author keywords

Daunorubicin; Doxorubicin; High performance liquid chromatography (HPLC); Pharmacokinetics

Indexed keywords

BODY FLUIDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICELLES; RATS;

AMMONIA SOLUTION; DAUNORUBICIN; DOXORUBICIN; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; METHANOL-WATER; MOBILE PHASIS; RAT PLASMA; SAMPLE PREPARATION; SIMPLE++;

PHARMACOKINETICS;

ACETONITRILE; AMMONIA; DAUNORUBICIN; DOXORUBICIN; FORMIC ACID; METHANOL; WATER;

ACCURACY; ANALYTICAL ERROR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; ENCAPSULATION; FEMALE; FLOW RATE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; NONHUMAN; PRECIPITATION; RAT; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE;

RATTUS;

EID: 65949101227     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1054     Document Type: Article

References (20)

1. Alvarez-Cedron L, Sayalero ML and Lanao JM. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. Journal of Chromatography B 1999; 2: 271-278.
2. Arnold RD, Slack JE and Straubinger RM. Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. Journal of Chromatography B 2004; 2: 141-152.
3. Charrois GJ and Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochimica Biophysica Acta 2004; 1-2: 167-177.
4. Chin DL, Lum BL and Sikic BI. Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. Journal of Chromatography B 2002; 2: 259-269.
5. de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G and Sparreboom A. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Analytical Biochemistry 1999; 2: 216-221.
6. Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C and Del Tacca M. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Therapeutic Drug Monitoring 1999; 3: 367-375.
7. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Research 1992; 4: 891-896.
8. Gabizon A, Shmeeda H and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clinical Pharmacokinetics 2003; 5: 419-436.
9. Gilbert CM, McGeary RP, Filippich LJ, Norris RL and Charles BG. Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinol in parrot plasma. Journal of Chromatography B 2005; (1-2): 273-276.
10. Hu T, Le Q, Wu Z and Wu W. Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-beta-hydroxybutyrate microspheres. Journal of Pharmaceutical and Biomedical Analysis 2007; 1: 263-269.
11. Kataoka K, Harada A and Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Advances in Drug Delivery Review 2001; 1: 113-131.
12. Lachâtre F, Marquet P, Ragot S, Gaulier JM, Cardot P and Dupuy JL. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. Journal of Chromatography B 2000; 2: 281-291.
13. Nishikawa M and Hashida M. Pharmacokinetics of anticancer drugs, plasmid DNA, and their delivery systems in tissue-isolated perfused tumors. Advances in Drug Delivery Review 1999; 1-2: 19-37.
14. Reddy LH, Meda N and Murthy RR. Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood - the silver nitrate artifact. Acta Pharmaceutica 2005; 1: 81-91.
15. Speth PA, van Hoesel QG and Haanen C. Clinical pharmacokinetics of doxorubicin. Clinical Pharmacokinetics 1988; 1: 15-31.
16. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P and Engineer FN. Effects of verapamil on the acute toxicity of doxorubicin in vivo. Journal of National Cancer Institute 1992; 21: 1653-1660.
17. Steinherz LJ, Steinherz PG, Tan CT, Heller G and Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Journal of the American Medical Association 1991; 12: 1672-1677.
18. Tang N, Du GJ, Wang N, Liu CC, Hang HY and Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. Journal of the National Cancer Institute 2007; 13: 1004-1015.
19. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews in Drug Discovery 2005; 2: 145-160.
20. van Asperen J, van Tellingen O and Beijnen JH. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. Journal of Chromatography B 1998; 1-2: 129-143.